Abstract

Zeina A. Althanoon, Nasih A.Alkazzaz.

Objective: Beta thalassemia is the most common congenital hemolytic anemia in all over the world. It is characterized by a profound ineffective erythropoiesis making regular blood transfusions is essential for survival, while a serious problem of iron overload arise due to inability of human body to excrete accumulated iron of blood transfusion which is a lethal health problem that can be managed by iron chelators. Iron overload may occur in kidney after blood transfusion. The objective of this study is to evaluate the effects of iron chelators on markers of renal function in transfusion dependent β- Thalassemic patients who were treated with either deferasirox(DFX) or deferoxamine (DFO)
Methods: In this cross-sectional study, the total number of subjects participated was 164 (patients and controls) with age range (3-21) years old divided into 108 patients with homozygous β- thalassemia major. The patients were subdivided into: The DFO group (54 patients) were used Deferoxamine and the DFX group (54 patients) were used Deferasirox. The remaining 56 were enrolled as apparently healthy subjects (Control). Blood samples were collected from each patient and control subject at the thalassemic Center of ibn Al-Atheer Teaching Hospital in Nineveh Province, Iraq. The Parameters tested in this study, included laboratory measurements of serum ferritin, renal function tests (serum urea, serum creatinine and creatinine clearance) and serum uric acid. Descriptive characteristics (weight
, height, and body mass index) were also collected during interviews with patients and controls with their relatives.
Results: Results illustrated a significant difference is present between the means of serum ferritin, (pË‚0.001), creatinine clearance(pË‚0.01) and creatinine (pË‚0.05) for patient group on DFO and control group. In addition, a significant difference is present between the means of serum ferritin, uric acid (pË‚0.001), urea (pË‚0.05) for patients’ group on DFX and control group. A significant difference is present in serum ferritin (pË‚0.001), urea, creatinine clearance, uric acid (pË‚0.01), creatinine (pË‚0.05) between the two patient groups (DFO and DFX).
Conclusion: It was concluded from this study that changes in renal function markers in patients with β-thalassemic patients may be attributed to chronic anemia, iron overload as well as to deferoxamine or deferasirox therapy. These changes could have any long-term effects in β- thalassemic patients. In addition, the same urine markers did not correlate with age, indicating that chronic anemia or treatment with either deferoxamine or deferasirox are not related to renal dysfunction in β-thalassemic patients.

How to Cite this Article

Pubmed Style Althanoon ZA, A.Alkazzaz N. Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia. SRP. 2020; 11(11): 214-222. doi:10.31838/srp.2020.11.31 Web Style Althanoon ZA, A.Alkazzaz N. Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia. http://www.sysrevpharm.org/?mno=9806 [Access: March 29, 2021]. doi:10.31838/srp.2020.11.31 AMA (American Medical Association) Style Althanoon ZA, A.Alkazzaz N. Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia. SRP. 2020; 11(11): 214-222. doi:10.31838/srp.2020.11.31 Vancouver/ICMJE Style Althanoon ZA, A.Alkazzaz N. Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia. SRP. (2020), [cited March 29, 2021]; 11(11): 214-222. doi:10.31838/srp.2020.11.31 Harvard Style Althanoon, Z. A. & A.Alkazzaz, . N. (2020) Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia. SRP, 11 (11), 214-222. doi:10.31838/srp.2020.11.31 Turabian Style Althanoon, Zeina A., and Nasih A.Alkazzaz. 2020. Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia. Systematic Reviews in Pharmacy, 11 (11), 214-222. doi:10.31838/srp.2020.11.31 Chicago Style Althanoon, Zeina A., and Nasih A.Alkazzaz. "Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia." Systematic Reviews in Pharmacy 11 (2020), 214-222. doi:10.31838/srp.2020.11.31 MLA (The Modern Language Association) Style Althanoon, Zeina A., and Nasih A.Alkazzaz. "Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia." Systematic Reviews in Pharmacy 11.11 (2020), 214-222. Print. doi:10.31838/srp.2020.11.31 APA (American Psychological Association) Style Althanoon, Z. A. & A.Alkazzaz, . N. (2020) Comparison of The Effects Of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia. Systematic Reviews in Pharmacy, 11 (11), 214-222. doi:10.31838/srp.2020.11.31